Cover Image
Market Research Report

Global Hepatitis B Therapeutics Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 756749
Published Content info 110 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Hepatitis B Therapeutics Market 2018-2022
Published: December 4, 2018 Content info: 110 Pages
Description

About this market:

Global hepatitis B therapeutics market is fragmented market, as many pharmaceutical companies are developing drugs for the treatments of hepatitis B. Also, several companies are forming collaborations to increase their research toward the hepatitis B drug development. These types of strategic collaboration between the pharmaceutical companies will propel the hepatitis B therapeutics development and lead to increase the growth of the market during our forecast period. This will boost the growth of the hepatitis B therapeutics market at a CAGR of over 2% during the forecast period.

Market Overview:

Increasing prevalence of hepatitis B in infants

The increase in the prevalence of hepatitis B in infants, the companies are developing various and drugs against hepatitis B virus. This leads to an increase in the global market during the forecast period.

Low accessibility due to high cost of hepatitis B treatment

One of the major problems from the treatment of hepatitis B is that not all the approved drugs are accessible to people and some are not affordable. Therefore, low accessibility due to the high cost of hepatitis B treatment is one the biggest challenges for the goal aiming to eliminate hepatitis B during our forecast period.

For the detailed list of factors that will drive and challenge the growth of the hepatitis B therapeutics market during the 2018-2022, view our report.

Competitive Landscape:

The global hepatitis B therapeutics market is fairly fragmented and the market being in growth phase, the competition among companies is intense. Several companies are forming collaborations to increase their research toward the hepatitis B drug development. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR23586

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY APPLICATION

  • Segmentation by application
  • Comparison by application
  • Drugs - Market size and forecast 2017-2022
  • Vaccines - Market size and forecast 2017-2022
  • Market opportunity by application

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Strategic alliances
  • Strong pipeline
  • New technological advancements

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • GlaxoSmithKline
  • Merck Sharp & Dohme

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global infectious disease treatment market segmentation
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2017
  • Exhibit 07: Validation techniques employed for market sizing 2017
  • Exhibit 08: Global hepatitis B therapeutics market - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 09: Global hepatitis B therapeutics market - Year-over-year growth 2018-2022 (%)
  • Exhibit 10: Five forces analysis 2017
  • Exhibit 11: Five forces analysis 2022
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 20
  • Exhibit 18: Pipeline landscape by development phase
  • Exhibit 19: Global hepatitis B therapeutics pipeline: Overview
  • Exhibit 20: Application - Market share 2017-2022 (%)
  • Exhibit 21: Comparison by application
  • Exhibit 22: Drugs - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 23: Drugs - Year-over-year growth 2018-2022 (%)
  • Exhibit 24: Vaccines - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 25: Vaccines - Year-over-year growth 2018-2022 (%)
  • Exhibit 26: Market opportunity by application
  • Exhibit 27: Customer landscape
  • Exhibit 28: Global - Market share by geography 2017-2022 (%)
  • Exhibit 29: Regional comparison
  • Exhibit 30: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 31: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 32: Top 3 countries in Americas
  • Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 35: Top 3 countries in EMEA
  • Exhibit 36: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 37: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 38: Top 3 countries in APAC
  • Exhibit 39: Market opportunity
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendors covered
  • Exhibit 43: Vendor classification
  • Exhibit 44: Market positioning of vendors
  • Exhibit 45: Bristol-Myers Squibb - Overview
  • Exhibit 46: Bristol-Myers Squibb - Business segments
  • Exhibit 47: Bristol-Myers Squibb - Organizational developments
  • Exhibit 48: Bristol-Myers Squibb - Geographic focus
  • Exhibit 49: Bristol-Myers Squibb - Key offerings
  • Exhibit 50: Bristol-Myers Squibb - Key customers
  • Exhibit 51: F. Hoffmann-La Roche - Overview
  • Exhibit 52: F. Hoffmann-La Roche - Business segments
  • Exhibit 53: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 54: F. Hoffmann-La Roche - Geographic focus
  • Exhibit 55: F. Hoffmann-La Roche - Segment focus
  • Exhibit 56: F. Hoffmann-La Roche - Key offerings
  • Exhibit 57: F. Hoffmann-La Roche - Key customers
  • Exhibit 58: Gilead - Overview
  • Exhibit 59: Gilead - Business segments
  • Exhibit 60: Gilead - Organizational developments
  • Exhibit 61: Gilead - Geographic focus
  • Exhibit 62: Gilead - Key offerings
  • Exhibit 63: Gilead - Key customers
  • Exhibit 64: GlaxoSmithKline - Overview
  • Exhibit 65: GlaxoSmithKline - Business segments
  • Exhibit 66: GlaxoSmithKline - Organizational developments
  • Exhibit 67: GlaxoSmithKline - Geographic focus
  • Exhibit 68: GlaxoSmithKline - Segment focus
  • Exhibit 69: GlaxoSmithKline - Key offerings
  • Exhibit 70: GlaxoSmithKline - Key customers
  • Exhibit 71: Merck Sharp & Dohme - Overview
  • Exhibit 72: Merck Sharp & Dohme - Business segments
  • Exhibit 73: Merck Sharp & Dohme - Organizational developments
  • Exhibit 74: Merck Sharp & Dohme - Geographic focus
  • Exhibit 75: Merck Sharp & Dohme - Segment focus
  • Exhibit 76: Merck Sharp & Dohme - Key offerings
  • Exhibit 77: Merck Sharp & Dohme - Key customers
Back to Top